MedTrace Logo

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

NCT01231633 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2018-04-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).

Conditions

  • Macular Edema
  • Central Retinal Vein Occlusion

Interventions

DRUG

Ozurdex

Ozurdex, 0.7mg dexamethasone

DRUG

Avastin

Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.

Sponsors & Collaborators

  • Long Island Vitreoretinal Consultants

    lead OTHER

Principal Investigators

  • Vincent A Deramo, M.D · Long Island Vitreoretinal Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01231633 on ClinicalTrials.gov